| Bioactivity | Lucicebtide (Compound ST101) is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide arrests cell cycle at G0/G1 phase. Lucicebtide exhibits cytotoxicity in cancer cells. Lucicebtide exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model[1]. |
| CAS | 2407100-74-5 |
| Sequence | d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg} |
| Shortening | d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg} |
| Formula | C208H345N69O55S |
| Molar Mass | 4724.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Darvishi E, et al., Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β. Mol Cancer Ther. 2022 Nov 3;21(11):1632-1644. |
Lucicebtide
CAS: 2407100-74-5 F: C208H345N69O55S W: 4724.46
Lucicebtide (Compound ST101) is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide bind
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.